- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07648082
Breathlessness Perceptions Within Respiratory Diseases (BiRD)
Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases
Studienübersicht
Status
Detaillierte Beschreibung
Breathlessness is a debilitating symptom that results in poorer quality of life, increased hospitalisations, and increased mortality. Breathlessness is a complex multi-dimensional sensation with established bio-psycho-social influences (Hayen et al., 2013) that are likely to interact, though the mechanisms or relative contributions of these interactions are unknown (Oxley & Macnaughton, 2016). Breathlessness is a hallmark feature of respiratory disease and is the primary reason for seeking healthcare advice and treatments. Though currently breathlessness management follows a one-size fits all approach and does not pay consideration to the unique and individual experience of breathlessness.
The breathing thinking functioning (BTF) model of breathlessness is a theoretical framework that attempts to explain this complex and multifactorial symptom, however it lacks scientific premise. Highlighting that physiology, psychology and function will all play a role in determining breathlessness for the individual. An additional complication, that is seldom explored is disordered breathing patterns. This is potentially bi-directional where by severe breathlessness could contribute to disordered breathing and/or disordered breathing could lead to severe breathlessness. There is currently no objective marker of disordered breathing pattern however, use of optoelectronic plethysmography (OEP) has shown promise in quantifying this phenomenon (Smyth, 2021). OEP is a novel technique, utilising 3-dimensional motion capture, and can be measured during exercise, using a cardiopulmonary exercise testing, which allows for monitoring of breathlessness and breathing pattern during exercise, commonly reported as troublesome by patients. OEP has been used in Chronic Obstructive Pulmonary Disease to assess hyperinflation, though evidence within respiratory disease is at its infancy, and has not been explored alongside other factors to understand the contribution of multiple factors of breathlessness. Therefore, there is a current gap in the literature exploring the interaction(s) of factors contributing to breathlessness severity, including the objective analysis of breathing pattern. Further understanding the breathlessness in this way could lead to personalisation or treatments increasing their effectiveness, and improving health and quality of life. The project will quantitatively measure breathlessness perception, alongside objective cardiorespiratory measures and background health and well-being data as well as OEP breathing pattern data (such as compartment contribution and inter-compartment asynchrony). This will allow an understanding of how each of these factors may affect interventions and differences in breathlessness experience and presentation, and subsequently the acceptability of breathlessness.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Enya Dr. Daynes, PhD
- Telefonnummer: +44 0116 273 0333
- E-Mail: e.daynes@nhs.net
Studieren Sie die Kontaktsicherung
- Name: Iridu Udanthi Basnayake, MSc
- Telefonnummer: 0116 273 0333
- E-Mail: iub3@leicester.ac.uk
Studienorte
-
-
Leicestershire
-
Leicester, Leicestershire, Vereinigtes Königreich, LE3 9QP
- Rekrutierung
- Glenfield Hospital
-
Kontakt:
- Enya Daynes, PhD
- Telefonnummer: +44 +44 1162730333
- E-Mail: e.daynes@nhs.net
-
Hauptermittler:
- Enya Daynes, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
• Aged 18 or over up to 100
- Known respiratory diagnosis* OR Healthy control**
- Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale
- Able to communicate in English
- Able to attend two study visits
Able to provide written informed consent
- Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.
- Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.
Exclusion Criteria:
• Unstable disease or undergoing investigations for unexplained symptoms
- Undergone a surgery within past six weeks
- Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)
- BMI ≥ 35kg/m2
- Unable to communicate in English
- Unable to provide written informed consent
- Unable to abstain from smoking for 8 hours prior to testing
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
50 participants with a respiratory disease and 25 health controls will be recruited.
Inclusion criteria is:
Participants are excluded if,:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Breathing pattern regional contribution parameters
Zeitfenster: From June 2025 to July 2026
|
Optoelectronic plethysmography allows to quantify how different thoracic compartments contribute to the overall tidal volume through regional contribution parameters.
These regional contributions are expressed as percentages.
|
From June 2025 to July 2026
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Breathing pattern-Timing parameters-Recording duration
Zeitfenster: From June 2025 to July 2026
|
The duration will be recorded in minutes and seconds to state how long a specific measurement lasted.
|
From June 2025 to July 2026
|
|
Breathing pattern-Timing parameters- Sampling frequency rate
Zeitfenster: From June 2025 to July 2026
|
This is one of the core timing parameter.
The system uses sample at 60-120 Hz (frames per second).
|
From June 2025 to July 2026
|
|
Breathing pattern-Timing Parameters- Number of respiratory cycles analysed
Zeitfenster: From June 2025 to July 2026
|
This parameter is important to give an indication of data adequacy.
It will be reported in whole numbers.
|
From June 2025 to July 2026
|
|
Breathing pattern-Ratio parameters-Compartmental contributions
Zeitfenster: From June 2025 to July 2026
|
All the parameters will be expressed as percentages.
(%RCp, %RCa and %AB) typically ranging from (0-100%)
|
From June 2025 to July 2026
|
|
Breathing pattern- Phase angle parameters
Zeitfenster: From June 2025 to July 2026
|
These parameters will be meausred by the degree ranging from 0 to 180 (Complete paradox)
|
From June 2025 to July 2026
|
|
Breathing pattern-ratio parameters- Temporal ratios
Zeitfenster: From June 2025 to July 2026
|
This will be reported in decimal values.
(Ti/Ttot, Ti/Te ratio, IE ratio inverse of Ti/Te) Ti-Inspiratory time Te-Expiratory time Ttot-Total breath duration
|
From June 2025 to July 2026
|
|
Rate of Perceived Exertion (RPE) and Borg breathlessness scale
Zeitfenster: From June 2025 to July 2026
|
Provides details about how breathlessness one feels and how hard the exercise is during exercise .
Both these scales will be reported in numbers.
The RPE is from 6-20 and the Borg scale is from 0-10.
Higher scores will indicate worst breathlessness and exertion from the performing exercise.
|
From June 2025 to July 2026
|
|
Spirometry
Zeitfenster: From June 2025 to July 2026
|
Lung Function parameters such as FEV1 -Forced Expiratory Volume, FVC -Forced Vital Capacity, FEV1/FVC ratio will be obtained using Spirometry (Spirotrac).
Presented in litres can be converted to percentage.
Depending on the guidelines usually if the FEV1/ FVC ratio<= 0.7 it can be said that there is an airway obstruction.
Lower value indicates a higher level of breathlessness.
The GOLD classification criteria is usually used to describe the severity.
The values can further be explained as obstructive or restrictive by looking at the FVC%.
A lower FVC% predicted will indicate worse restriction.
|
From June 2025 to July 2026
|
|
Modified Medical Research Council Dyspnea Scale (mMRC)
Zeitfenster: From June 2025 to July 2026
|
Scale that grades the severity of breathlessness based on the level of physical activity that provokes the symptom.
The scale is from 0-4.
Lower values indicate less severity of breathlessness while higher values indicate severe breathlessness.
|
From June 2025 to July 2026
|
|
Dysponea-12 (D-12)
Zeitfenster: From June 2025 to July 2026
|
The Dyspnoea-12 (D-12) is a patient-reported outcome measure designed to assess the multidimensional nature of breathlessness severity through both physical and affective components.
The questionnaire has 12 questions where the participant will be asked to put a tick to any box from none, mild, moderate and severe.
|
From June 2025 to July 2026
|
|
Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: From June 2025 to July 2026
|
Self-report questionnaire designed to screen for clinically significant anxiety and depression in medical populations.
The participant will be asked to underline their answers for all the questions.
The questionnaire includes a 'A' category and a 'D' category.
Scores are given to both catergories from 0-3.
At the end the two catergoeies will be calculated separately.
|
From June 2025 to July 2026
|
|
Breathlessness catastrophising scale (BCS)
Zeitfenster: From June 2025 to July 2026
|
A measure designed to assess catastrophic thinking patterns specifically related to breathlessness.
BCS is a 13 item questionnaire where the participant will have to tick one of the boxes for each question starting from not at all, to a slight degree, to a moderate degree, to a great degree and all the time.
|
From June 2025 to July 2026
|
|
Euroqol 5-Domain-5-Level (EQ5D-5L)
Zeitfenster: From June 2025 to July 2026
|
A standardised generic health-related quality of life instrument designed to provide a simple, comprehensive measure of health status across diverse populations and conditions.
The questionnaire asseses 4 sections where the participant will have to select one option from each section.
The questionnaire is assessing the health related quality of life interms of that day and not in general.
At the end of the questionnaire there is a separate scale from 0-100 where the participant will have to place an x mark on the scale and write that score in a box which will indicate how they feel on that specific day.
|
From June 2025 to July 2026
|
|
Nijmegen Questionnaire (NQ)
Zeitfenster: From June 2025 to July 2026
|
An instrument designed to assess symptoms associated with hyperventilation syndrome and dysfunctional breathing patterns.
The questionnaire contains 16 symptoms.
The participant will be required to place a tick in one of the boxes for each question.
Answers include, never, rarely, sometimes, often and very often.
|
From June 2025 to July 2026
|
|
Breathing pattern assessment tool (BPAT)
Zeitfenster: From June 2025 to July 2026
|
Visible characteristics of breathing patterns during rest where the participant will be asked to rest against a back seat.
The participant will be observed for 1 minute by a member of the study team where they will have to breathe in and out as they usually do.
During that time the team member will observe whether the breathing is rhythmical, whether the participant is using using their chest, abdomen or both for breathing, whether their inspiratory and expiratory flows are silent, audible or loud.
Other questrions that will be answered by the team member would be channel of inspiration and expiration, air hunger, rhythm as well the team member will also calculate the respiratory rate within a 1 minute.
Scores will be given from 0-2 and at the end the total score will be calculated.
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise testing -Gas Exchange Parameters
Zeitfenster: From June 2025 to July 2026
|
Peak Oxygen Uptake (VO2 peak) meausured through mL/min or L/min, If >=85 is normal, 65-84 is mildly reduced, 50-64 is moderately reduced and <50 is severely reduced. Carbon Dioxide Output (VCO2) and RER (VCO2/VO2) meausured through mL/min or L/min, VCO2 roughly rises parallel to VO2. The volume of CO₂ produced per minute by the body reflects the metabolic CO₂ production from aerobic and anaerobic metabolism combined. The respiratory exchange ratio which is RER gives a clear indication whether the test was maximal effort or not. RER >=1.10 is the key cutoff. AT will all be meausured through mL/min or L/min. Normal: typically > 40% of predicted VO₂ max, or ≥ 11 ml/kg/min Higher AT = better - indicates the body can sustain aerobic metabolism at higher workloads before switching to anaerobic system. |
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing- Ventilatory Parameters (Minute Ventilation)
Zeitfenster: From June 2025 to July 2026
|
Minute Ventilation will be measured at maximal exercise.
The measures will be stated in L/min.
Minute ventilation is assess the ventilatory capacity.
Usually the ventilatory reserve utilizes <60 to 70% of the maximum voluntary ventilation which is considered healthy.
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing- Ventilatory Parameters (Tidal Volume)
Zeitfenster: From June 2025 to July 2026
|
Tidal Volume will be measured by L or mL.
It is amount of air that moves in and out of the lung.
During exercise, it increases linearly before plateauing indicating whether a participant's exercise capacity is physically restricted due to lung mechanics.
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing- Ventilatory Parameters ( Respiratory Rate)
Zeitfenster: From June 2025 to July 2026
|
This is measured by breaths per minute. The amount of breaths taken will indicate how your brain and lungs are functioning to clear the carbondioxide which will help to maintain the chemical balance. Resting phase 12 to 20 breaths/min -Baseline range Peak Exercise 35 to 45 breaths/min -Normal physiological range for healthy adults. |
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing-Ventilatory Parameters (MVV and BR)
Zeitfenster: From June 2025 to July 2026
|
MVV- Maximal Voluntary Ventilation and BR-Breathing Reserve both are measured by L/min.
This determines whether a patient's exercise capacity is limited by their lungs or by their heart and/or muscles.
MVV represents a participants absolute ceiling for breathing capacity, while BR measures how much of that capacity is left over at peak exercise.
If MVV >=80% it is considered good and if <80% it is considered bad.
Whereas for BR, if >11L/min is considered as the lungs still having more capacity left after exercising and <=11L/min is considered that the patient is exhausted and their breathing capacity has reached the limit.
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing- Ventilatory Efficiency Parameters
Zeitfenster: From June 2025 to July 2026
|
VE/VO2 slope and VE/VCO2 at AT are measured by a dimensionless ratio.
VE/VCO2 is considered good when it is between 23-30 and bad when it is >34.
VE/VO2 is considered good when it is between 25 to 33 and bad when it is >36
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing-HR reserve
Zeitfenster: From June 2025 to July 2026
|
This will be measured through bpm.
It is the difference between predicted maximum heart rate and the actual peak heart rate.
<15bpm indicates a good response whereas >=15bpm indicates a poor response.
|
From June 2025 to July 2026
|
|
Cardiopulmonary Exercise Testing- Work Rate
Zeitfenster: From June 2025 to July 2026
|
This will be reported in W (Watts). Achieving >= 80% of the predicted work rate is considered a good response whereas <80% would be considered as a poor response.
|
From June 2025 to July 2026
|
|
Oxygen Saturation
Zeitfenster: From June 2025 to July 2026
|
This will be reported through % (Percentage).
95-100%- Good 93-94%- Borderline <92%- Bad
|
From June 2025 to July 2026
|
|
Blood pressure
Zeitfenster: From June 2025 to July 2026
|
This will be measured by mmHg Before the test (At rest) >=200/110- Contraindication not to perform the exercise test <90/60- Too low for the baseline During the exercise test, If the systolic value exceeds 190 or 210 indicates a severe hypertension A critical stop would be a systolic value exceeding 250 or a diastolic value exceeding 115. After the test, The blood pressure should return to near or actual borderline taken during rest. |
From June 2025 to July 2026
|
|
Height
Zeitfenster: From June 2025 to July 2026
|
Measured through cm.
|
From June 2025 to July 2026
|
|
Weight
Zeitfenster: From June 2025 to July 2026
|
Measured by kg (Kilograms).
|
From June 2025 to July 2026
|
|
Body Mass Index
Zeitfenster: From June 2025 to July 2026
|
Calculated manually via height and weight measurements.
Will be presented as kgm squared.
This study has a cut off value which is not involving participants above 35.
|
From June 2025 to July 2026
|
|
Heart rate variability (HRV) - Holter Monitor
Zeitfenster: From June 2025 to May 2026
|
SDNN- Standard Deviation of normal-to-normal R-R intervals, SDANN-Standard Deviation of the mean R-R intervals, RMSSD-Square root of the mean squared difference of successive R-R intervals are all measued by milliseconds (ms).
|
From June 2025 to May 2026
|
|
Heart Rate Variability-Holter Monitor
Zeitfenster: From June 2025 to July 2026
|
LF-Low Frequency Power and HF-High Frequency Power are both measured by milliseconds squared or absolute units. LF Absolute 300 to 1500- considered good LF Absolute <100 -considered bad/abnormal HF Absolute 200 to 1000- considered good HF Absolute <50- considered bad/abnormal |
From June 2025 to July 2026
|
|
Heart Rate Variability-Holter Monitor
Zeitfenster: From June 2025 to July 2026
|
LF/HF ratio will be a dimensionless ratio represented without any units. High rates will suggest of sympathetic predominance. At rest Good range will be 1.0-2.0 Bad range >5 or <0.5 |
From June 2025 to July 2026
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Enya Daynes, PhD, University Hospitals, Leicester
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Pritchard A, Burns P, Correia J, Jamieson P, Moxon P, Purvis J, Thomas M, Tighe H, Sylvester KP. ARTP statement on cardiopulmonary exercise testing 2021. BMJ Open Respir Res. 2021 Nov;8(1):e001121. doi: 10.1136/bmjresp-2021-001121.
- Oxley R, Macnaughton J. Inspiring change: humanities and social science insights into the experience and management of breathlessness. Curr Opin Support Palliat Care. 2016 Sep;10(3):256-61. doi: 10.1097/SPC.0000000000000221.
- Hayen A, Herigstad M, Pattinson KT. Understanding dyspnea as a complex individual experience. Maturitas. 2013 Sep;76(1):45-50. doi: 10.1016/j.maturitas.2013.06.005. Epub 2013 Jul 10.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Lungenkrankheit
- Atemstörungen
- Bronchialerkrankungen
- Lungenerkrankungen, obstruktive
- Überempfindlichkeit der Atemwege
- Überempfindlichkeit, sofort
- Überempfindlichkeit
- Anzeichen und Symptome, Atmung
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Lungenerkrankung, chronisch obstruktiv
- Asthma
- Erkrankung
- Lungenerkrankungen, Interstitial
- Erkrankungen der Atemwege
- Dyspnoe
- Bronchiektasen
Andere Studien-ID-Nummern
- 172675
- NIHR203327 (Andere Zuschuss-/Finanzierungsnummer: NIHR Biomedical Research Centre Leicester)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .